Tirzepatide is an antidiabetic medication used for the treatment of Type 2 Diabetes and is given by weekly subcutaneous injection (under the skin). Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar control. Tirzepatide is a GIP-analogue that activates both the GLP-1 and GIP receptors, leading to improved blood glucose control.
A study published in the journal Pharmaceuticals (Basel) was conducted to verify the effectiveness of Tirzepatide on glycated haemoglobin (HbA1c), fasting serum glucose (mg/dL), and body weight (kg) in 2783 people with uncontrolled Type 2 Diabetes. The study found that the
group on tirzepatide treatment had greater lowering of values across all parameters - HbA1c, fasting serum glucose and body weight. Improvement in the HbA1c levels was still maintained at weeks 26 and 40 from the long-term trials
